News Archive - Page 2 of 2 - Navrogen : Navrogen

July 1, 2021

Navrogen Signs Commercial Evaluation License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immunosuppressed Cancers

Navrogen has signed a commercial evaluation license agreement with the National Cancer Institute (NCI) of the National Institutes of Health (NIH) for the commercialization of tumor targeted therapies to...

January 11, 2021

Navrogen Establishes Research Collaboration with The National Cancer Institute to Test Mesothelin-Targeting Therapies for Cancers Affected by Humoral Immuno-Oncology Factors

Navrogen, Inc. and the National Cancer Institute (NCI), part of the National Institutes of Health, have established a research collaboration aimed at testing mesothelin-targeting therapies for the treatment of...

September 29, 2020

Navrogen Signs Commercial License Agreement with The National Cancer Institute to Develop Next-Generation Therapies for Immuno-suppressed Cancers

Navrogen announced today that it has signed a license agreement with the National Cancer Institute (NCI) for the commercialization of mesothelin-targeting agents.

September 14, 2020

Navrogen Awarded National Cancer Institute Grant to Develop Next-Generation Rituximab with Enhanced Therapeutic Effects

Navrogen announced today that it has been awarded a National Cancer Institute (NCI) R03 Grant to support its NAV-006 program involving the development of a next-generation rituximab that is...

February 4, 2020

Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates to Treat Humoral Immuno-Suppressed Cancers

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, and Levena Biopharma, a company specialized in developing antibody drug conjugates (ADCs), announced today the...

January 31, 2020

Navrogen Opens R&D Operations at Cheyney University

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the opening of its R&D operations at the Cheyney University science center located in Chester County, PA....

November 20, 2019

Navrogen Inc. and Lonza Sign Agreement to Use Lonza’S GS Gene Expression System® for Navrogen’s Anti-HIO Targeting Agents

Navrogen Inc. and Lonza Pharma & Biotech announced today that they have entered a licensing agreement for the production of Navrogen's biotherapeutics using Lonza’s GS Xceed Expression System. Navrogen...

October 1, 2019

Navrogen Enters into CRADA with the U.S. National Cancer Institute to Develop Agents to Overcome Tumor-Mediated Immunosuppression

Navrogen, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI). The CRADA is focused...

September 17, 2019

Navrogen Announces the Closing of $3.2M Funding to Support its Humoral Immuno-Oncology Platform Discovery Technologies and Preclinical Pipeline

Navrogen, Inc. announced today that it has raised $3.2M in convertible note financing to support its operations, Humoral Immuno-Oncology (HIO) discovery platform and preclinical therapeutic pipeline activities. The financing...